SCHEMBL495864

SCHEMBL495864

CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)[C@H](O)CN1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 3/20 0.60
PSEN1 P49768 3/20 0.49
PSEN2 P49810 3/20 0.49
APH1B Q8WW43 3/20 0.49
NCSTN Q92542 3/20 0.49
APH1A Q96BI3 3/20 0.49
PSENEN Q9NZ42 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ATM Q13315 1/20 0.49
APP P05067 1/20 0.48
CTSL P07711 2/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
REN P00797 4/20 0.48
CTSS P25774 2/20 0.47
CTSB P07858 1/20 0.47
CTSK P43235 1/20 0.47
ACE P12821 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495862 1.00 KLK5 (0.60) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495686 0.99 KLK5 (0.59) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495688 0.99 KLK5 (0.59) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495781 0.90 KLK5 (0.55) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495779 0.90 KLK5 (0.55) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL12635649 0.88 KLK5 (0.55) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL496108 0.88 KLK5 (0.57) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL496107 0.88 KLK5 (0.57) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495732 0.87 KLK5 (0.57) KLK5PSEN1PSEN2APH1BNCSTN
SCHEMBL495731 0.87 KLK5 (0.57) KLK5PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 EP disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 KLK5 3927/4885PSEN1 3565/4885PSEN2 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.